HIV 1 News and Research

RSS

Bisexual men, women face prejudice and discrimination from both heterosexual, homosexual people

Men who identify themselves as heterosexual are three times more likely to categorize bisexuality as "not a legitimate sexual orientation," an attitude that can encourage negative health outcomes in people who identify as bisexual, according to an analysis led by University of Pittsburgh Graduate School of Public Health researcher Mackey Friedman, Ph.D., M.P.H.

5 Nov 2013

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).

5 Nov 2013

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Interim data presented today show that all patients (13/13) who reached their 4-week post-treatment follow-up have undetectable levels of hepatitis C virus (SVR4) after completing a 12-week regimen of faldaprevir, deleobuvir, PPI-668 and ribavirin.

4 Nov 2013

Stop L.A. Corruption: A new awareness campaign that highlights failures of LA County

Health and public policy advocates from AIDS Healthcare Foundation (AHF) will unveil 'Stop L.A. Corruption,' a new advocacy and awareness campaign highlighting the profound failures of Los Angeles County and its key elected and appointed officials in carrying out their sworn duties to serve and protect the nearly 10 million residents of the County.

4 Nov 2013

VG Life Sciences' peptide awarded US patent for HIV treatment

The United States Patent and Trademark Office has issued on October 15, 2013 Patent No.: US 8,557,764 covering the VG Life Sciences' peptide VG1177 for treating HIV infection.

31 Oct 2013

Mylan's revenues decrease 2% to $1.77B in third quarter 2013

Mylan Inc. today announced its financial results for the three and nine months ended September 30, 2013.

31 Oct 2013

GHIT Fund to host panel discussion to examine recent successes, setbacks in global health

The Global Health Innovative Technology Fund, along with the New York Academy of Sciences and Japan Society, will host a panel discussion - comprised of preeminent global health experts - to examine recent successes and setbacks in global health and what they see as the secret ingredient to moving a vaccine, cure or diagnostic across the finish line and into the field.

31 Oct 2013

New insights into human cytomegalovirus may lead to development of therapeutic interventions

New insights into how human cytomegalovirus, the leading cause of birth defects associated with infection spreads from pregnant mother to fetus and from organ to organ in newborns provides translational researchers an exciting new avenue for investigation that may lead to the development of therapeutic interventions.

31 Oct 2013

HIV infection, not antiretroviral therapy associated with risk for atherosclerosis

HIV infection, not antiretroviral therapy (ART), is associated with risk for atherosclerosis in patients with no history of smoking, particularly those infected for eight years or more.

31 Oct 2013

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.

31 Oct 2013

Study looks at the feasibility of Xpert test for TB in real-life clinical setting in southern Africa

The first randomised trial to measure the impact of the rapid Xpert MTB/RIF test for tuberculosis in a real-life clinical setting finds that it can be accurately performed by a non-specialist with minimal training, improves same-day diagnosis and time to starting treatment, and increases the number of people who start treatment after testing positive on day 1 by 50%, compared with conventional TB diagnostics.

30 Oct 2013

Cytrx announces Q3 2013 financial results, provides clinical update

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three and nine-month periods ended September 30, 2013, and provided a clinical update.

29 Oct 2013

EPFL and UNIL-CHUV scientists create first map of human HIV resistance

The key to future HIV treatment could be hidden right in our own genes. Everyone who becomes infected deploys defense strategies, and some even manage to hold the virus at bay without any therapy at all.

29 Oct 2013

Health law broadens coverage for millions with HIV, AIDS

Stateline reports how the health law will broaden benefits for many of the 1.1 million Americans infected with HIV, especially those who live in the 25 states that are expanding Medicaid. Meanwhile, the Obama administration stresses that information an individual submits to sign up for health coverage cannot be used to enforce immigration law.

29 Oct 2013

DPP-4 inhibitors may reduce risk of autoimmune diseases

Dipeptidyl peptidase-4 inhibitors commonly used to control blood sugar levels in people with type 2 diabetes may also reduce the risk of autoimmune diseases in these patients, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.

28 Oct 2013

Potentially active forms of HIV hiding in infected immune T cells may be 60-fold greater, say experts

Just when some scientists were becoming more hopeful about finding a strategy to outwit HIV's ability to resist, evade and otherwise survive efforts to rid it from the body, another hurdle has emerged to foil their plans, new research from Johns Hopkins shows.

25 Oct 2013

Study finds persistent deficiency in new therapeutics for neglected diseases

In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative and other researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development efforts. This continued 'fatal imbalance' in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world's poorest and most neglected patients.

25 Oct 2013

HIV-positive patients with high CD4 cell counts are not at increased risk for heart attacks

Patients who are HIV-positive and have high CD4 cell counts - or have a high number of white blood cells that fight infections - aren't at an increased risk for heart attacks compared to patients who are HIV-negative, according to a Kaiser Permanente study that appears in the current online issue of the Journal of Acquired Immune Deficiency Syndromes.

25 Oct 2013

Full and early treatment may cure babies with HIV

A report published in The New England Journal of Medicine provides confirmation of what researchers say is the first case of HIV remission in a child born with the virus.

24 Oct 2013

HIV 1 News and Research

Bisexual men, women face prejudice and discrimination from both heterosexual, homosexual people

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Stop L.A. Corruption: A new awareness campaign that highlights failures of LA County

VG Life Sciences' peptide awarded US patent for HIV treatment

Mylan's revenues decrease 2% to $1.77B in third quarter 2013

GHIT Fund to host panel discussion to examine recent successes, setbacks in global health

New insights into human cytomegalovirus may lead to development of therapeutic interventions

HIV infection, not antiretroviral therapy associated with risk for atherosclerosis

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

Study looks at the feasibility of Xpert test for TB in real-life clinical setting in southern Africa

Cytrx announces Q3 2013 financial results, provides clinical update

EPFL and UNIL-CHUV scientists create first map of human HIV resistance

Health law broadens coverage for millions with HIV, AIDS

DPP-4 inhibitors may reduce risk of autoimmune diseases

Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Potentially active forms of HIV hiding in infected immune T cells may be 60-fold greater, say experts

Study finds persistent deficiency in new therapeutics for neglected diseases

HIV-positive patients with high CD4 cell counts are not at increased risk for heart attacks

Full and early treatment may cure babies with HIV

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Automating research - solutions and best practices

Latest News